Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naïve Populations from a Phase 2b Open-Label Extension Study
08:30am - 08:30am EDT - March 19, 2022
08:30am - 08:30am EDT - March 19, 2022
Author(s):
- P. J. Mease
- A. Deodhar
- J. F. Merola
- I. B. McInnes
- D. Assudani
- R. Bajracharya
- J. Coarse
- B. Ink
- G. Schett
| Display Label | Action |
|---|---|
| PA0009-3-Yr-SE-TNFi-n_Submission | Download Resource |